| 体内研究: |
Dexelvucitabine (Reverset; d-d4FC; 33.3 mg/kg by i.v. or p.o.) has distribution and elimination half-lives (t1/2α and t1/2β, respectively) of 0.7 and 3.6 h in monkeys, respectively. The Cmax ranges from 21.1 to 47.5 μM. Dexelvucitabine has a favorable pharmacokinetic profile with a long half-life (4.71 and 10.75 h after administration by the intravenous [i.v.] and oral [p.o.] routes, respectively) in woodchucks. |
| 参考文献: |
1. Brenda I Hernandez-Santiago, et al. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51(6):2130-5. 2. L Ma, et al. Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob Agents Chemother. 1999 Feb;43(2):381-4. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.402 ml |
22.008 ml |
44.016 ml |
| 5 mM |
0.88 ml |
4.402 ml |
8.803 ml |
| 10 mM |
0.44 ml |
2.201 ml |
4.402 ml |
| 50 mM |
0.088 ml |
0.44 ml |
0.88 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |